Astrazeneca Completes KYM Agreement For CMG901

March 30, 2023 08:28 AM SAST | By Reuters

March 30 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901

* ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901

* CMG901 IS CURRENTLY BEING EVALUATED IN A PHASE I TRIAL FOR TREATMENT OF CLAUDIN 18.2-POSITIVE SOLID TUMOURS, INCLUDING GASTRIC CANCER

* PRELIMINARY RESULTS FROM TRIAL SHOWN ENCOURAGING PROFILE FOR CMG901, WITH EARLY SIGNS OF ANTI-TUMOUR ACTIVITY ACROSS DOSE LEVELS TESTED Source text for Eikon: Further company coverage:


Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.



Top LSE Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK